Relating to the fields of biotechnologies and
gene therapy, the invention provides application of a
gene modified
mesenchymal stem cell in
pulmonary fibrosis treatment. The
gene modified mesenchymal stem cells are obtained through: in-vitro isolated culture and amplification of a
mesenchymal stem cell (MSC) deriving from
bone marrow and an
umbilical cord, and recombinant adenovirus Ad-HGF mediated in-vitro modification of the MSC by a
hepatocyte growth factor (HGF). By
transplanting the gene modified MSC to a C57 mouse to intervene in
radiation induced
lung injury and
fibrosis, exudation of a plurality proteins including
albumin, IgM and the like from an alveolar space can be reduced, local inflammatory responses of the
lung can be alleviated, and expression of TNF-alpha, soluble ICAM-1 and
multiple factors is inhibited, expression of the profibrotic factor TGF-beta, the collagen gene col1 alpha 1 and col 3 alpha 1 can be inhibited, and pulmonary tissue
collagen fiber deposition is reduced. The expression results of endogenous HGF and its
receptor cmet show that endogenous HGF expression can be induced and endogenous MSC can home to injured parts. Therefore, the employment of HGF modified MSC in treatment of
lung injury and
fibrosis brought by various pathogenic causes is of great significance.